Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Patrick O Richard

Showing results (31-40 of 94) with videos related to

Pageof 10
Sort By:
Pharmaceuticals (Basel, Switzerland)|August 26, 2022
<sup>64</sup>Cu-DOTHA<sub>2</sub>-PSMA, a Novel PSMA PET Radiotracer for Prostate Cancer with a Long Imaging Time WindowMarie-Christine Milot, Ophélie Bélissant Benesty, Véronique Dumulon-Perreault, et al.
Clinical Genitourinary Cancer|September 26, 2017
Comparison of Surgery and Radiation as Local Treatments in the Risk of Locoregional Complications in Men Subsequently Dying From Prostate CancerJason Hu, Armen G Aprikian, Fabio L Cury, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|November 2, 2016
The uptake of active surveillance for the management of prostate cancer: A population-based analysisPatrick O Richard, Shabbir M H Alibhai, Tony Panzarella, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|November 2, 2016
The uptake of active surveillance for the management of prostate cancer: A population-based analysisPatrick O Richard, Shabbir M H Alibhai, Tony Panzarella, et al.
The Journal of Urology|June 26, 2016
Multilocular Cystic Renal Cell Carcinoma: Pathological T Staging Makes No Difference to Favorable Outcomes and Should be ReclassifiedJaimin R Bhatt, Michael A S Jewett, Patrick O Richard, et al.
Frontiers in Oncology|February 6, 2023
Theranostic <sup>64</sup>Cu-DOTHA<sub>2</sub>-PSMA allows low toxicity radioligand therapy in mice prostate cancer modelMarie-Christine Milot, Ophélie Bélissant-Benesty, Véronique Dumulon-Perreault, et al.
Urologic Oncology|February 14, 2017
Effect of statins as a secondary chemopreventive agent among individuals with non-muscle-invasive bladder cancer: A population-based analysisPatrick O Richard, Ardalan E Ahmad, Shaheena Bashir, et al.
The Journal of Urology|June 29, 2016
Stricter Active Surveillance Criteria for Prostate Cancer do Not Result in Significantly Better Outcomes: A Comparison of Contemporary ProtocolsMaria Komisarenko, Narhari Timilshina, Patrick O Richard, et al.
World Journal of Urology|February 25, 2026
Optimizing renal mass histology prediction with artificial intelligence using handcrafted radiomicsTeodora Boblea Podasca, Mahdi Ait Lhaj Loutfi, Marc-Antoine Blais, et al.
Cancer Cell International|February 27, 2025
MicroRNA profiling identifies VHL/HIF-2α dependent miR-2355-5p as a key modulator of clear cell Renal cell carcinoma tumor growthPatric M Page, Sonia A Dastous, Patrick O Richard, et al.
Pageof 10

Showing results (31-40 of 94) with videos related to

Sort By:
Pageof 10
Pharmaceuticals (Basel, Switzerland)|August 26, 2022
<sup>64</sup>Cu-DOTHA<sub>2</sub>-PSMA, a Novel PSMA PET Radiotracer for Prostate Cancer with a Long Imaging Time WindowMarie-Christine Milot, Ophélie Bélissant Benesty, Véronique Dumulon-Perreault, et al.
Clinical Genitourinary Cancer|September 26, 2017
Comparison of Surgery and Radiation as Local Treatments in the Risk of Locoregional Complications in Men Subsequently Dying From Prostate CancerJason Hu, Armen G Aprikian, Fabio L Cury, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|November 2, 2016
The uptake of active surveillance for the management of prostate cancer: A population-based analysisPatrick O Richard, Shabbir M H Alibhai, Tony Panzarella, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|November 2, 2016
The uptake of active surveillance for the management of prostate cancer: A population-based analysisPatrick O Richard, Shabbir M H Alibhai, Tony Panzarella, et al.
The Journal of Urology|June 26, 2016
Multilocular Cystic Renal Cell Carcinoma: Pathological T Staging Makes No Difference to Favorable Outcomes and Should be ReclassifiedJaimin R Bhatt, Michael A S Jewett, Patrick O Richard, et al.
Frontiers in Oncology|February 6, 2023
Theranostic <sup>64</sup>Cu-DOTHA<sub>2</sub>-PSMA allows low toxicity radioligand therapy in mice prostate cancer modelMarie-Christine Milot, Ophélie Bélissant-Benesty, Véronique Dumulon-Perreault, et al.
Urologic Oncology|February 14, 2017
Effect of statins as a secondary chemopreventive agent among individuals with non-muscle-invasive bladder cancer: A population-based analysisPatrick O Richard, Ardalan E Ahmad, Shaheena Bashir, et al.
The Journal of Urology|June 29, 2016
Stricter Active Surveillance Criteria for Prostate Cancer do Not Result in Significantly Better Outcomes: A Comparison of Contemporary ProtocolsMaria Komisarenko, Narhari Timilshina, Patrick O Richard, et al.
World Journal of Urology|February 25, 2026
Optimizing renal mass histology prediction with artificial intelligence using handcrafted radiomicsTeodora Boblea Podasca, Mahdi Ait Lhaj Loutfi, Marc-Antoine Blais, et al.
Cancer Cell International|February 27, 2025
MicroRNA profiling identifies VHL/HIF-2α dependent miR-2355-5p as a key modulator of clear cell Renal cell carcinoma tumor growthPatric M Page, Sonia A Dastous, Patrick O Richard, et al.
Pageof 10